Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses

@inproceedings{Schellenbacher2013EfficacyOR,
  title={Efficacy of RG1-VLP Vaccination against Infections with Genital and Cutaneous Human Papillomaviruses},
  author={Christina Schellenbacher and Kihyuck Kwak and Dieter Fink and Saeed Shafti-Keramat and Bettina J. Huber and Christoph Jindra and Helena Faust and Joakim Dillner and Richard Roden and Reinhard Kirnbauer},
  booktitle={The Journal of investigative dermatology},
  year={2013}
}
Licensed human papillomavirus (HPV) vaccines, based on virus-like particles (VLPs) self-assembled from major capsid protein L1, afford type-restricted protection against HPV types 16/18/6/11 (or 16/18 for the bivalent vaccine), which cause 70% of cervical cancers (CxCas) and 90% of genital warts. However, they do not protect against less prevalent high-risk (HR) types causing 30% of CxCa, or cutaneous HPV. In contrast, vaccination with the minor capsid protein L2 induces low-level immunity to… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Current status and future prospects for human papillomavirus vaccines

  • Archives of pharmacal research
  • 2017
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Development of AAVLP ( HPV 16 / 31 L 2 ) particles as broadly protective HPV vaccine candidate

K Nieto, M Weghofer, P Sehr
  • PLoS One
  • 2012
VIEW 1 EXCERPT